CLINICAL TRIAL...Risk Factors for Progressive Supranuclear Palsy (PSP)
 

Risk Factors for Progressive Supranuclear Palsy (PSP)

Official Study Title: Genetic and Environmental Risk Factors for PSP

Sponsor: National Institute on Aging (NIA)
Clinicaltrials.gov ID: NCT00431301
Study ID: 1 R01 AG024040-01A2
Last Updated Date: 14 May 2007
Trial Start Date: 01 Aug 2006

Trial Post date: 23 Apr 2007
Website URL: http://www.clinicaltrials.gov/ct/show/NCT00431301?order=2[B]Summary

Summary
PSP is a neurologic disorder of unknown origin that gradually destroys cells in specific areas of the brain, leading to serious and permanent problems with the control of gait and balance. The most obvious sign of the disease is an inability to aim the eyes properly, which occurs because of damage in the area of the brain that coordinates eye movements. Persons with PSP also often show alterations of behavior, including apathy as well as progressive frontal disturbances, problems with planning and multitasking.

This study will determine: (1) if there is an association between PSP and specific genes of interest; (2) if there is an association between PSP and occupational and/or environmental chemical exposures functionally or structurally similar to known parkinsonian toxicants; and (3) if hypertension or traumatic brain injury prior to symptom-onset is associated with PSP.

To disentangle the complex set of factors that contributes to PSP, this study involves 500 PSP cases, 500 age/gender matched primary controls, and 500 secondary controls for genetic confirmation. Understanding the cause of PSP may also help explain the causes of other related diseases such as Alzheimer's or Parkinson’s disease. This multidisciplinary team of movement disorder specialists, epidemiologists, geneticists, biostatisticians, industrial hygienist and toxicologist is well suited to unravel the etiology of PSP.

Enrollment
Expected Enrollment: 1500


Trial Phase
Study Phase: Not Specified (About Phases)

Symptoms
# Trial does not treat PD symptoms

Time Commitment
Length of Time Commitment: Less than six months
Frequency of office visits:

Eligibility
Minimum Age: 40
Trial accepts healthy volunteers


Inclusion Criteria

• Able to visit the screening site for diagnostic confirmation
• Able to participate in a one-hour telephone interview
• Diagnosis of PSP

Exclusion Criteria

• Unable to communicate by telephone
• Cognitive disturbances
• Diagnosis of other major neurological disorders other than PSP

Primary Contact
Christopher Cunningham, Ph.D. & Whitney Rogers, BA
Study Coordinators
University of Louisville
Phone : 866-777-0448
info@pspstudy.com
Louisville, KY 40202
USA

Local Contacts
Rebecca McMurray
Study Coordinator
University of Alabama
Phone : 205-996-4034
Birmingham, AL 35233
USA

Site opening soon
University of California at Los Angeles (UCLA)
Los Angeles, CA 90095
USA

Audrey Strongosky
Study Coordinator
Mayo Clinic Jacksonville
Phone : 904-953-6096
Jacksonville, FL 32224
USA

Carol Ingram
Study Coordinator
Emory College of Medicine
Phone : 404-728-6859
Atlanta, GA 30322
USA

Maura Deeley
Study Coordinator
University of Maryland
Phone : 410-328-7816
Baltimore, MD 21201
USA

David Korosec
Study Coordinator
Case Western University
Phone : 216-844-1880
Cleveland, OH 44106
USA

Christine Hunter
Study Coordinator
Baylor College of Medicine
Phone : 713-798-3951
Houston, TX 77030
USA

Attachment 1410

Full Details:

PDTrials.org http://www.pdtrials.org/front/trial_...p?trial_id=161

• All Trials
• By Trial Type
• By Symptom
• By Location

ClinicalTrials.gov http://clinicaltrials.gov/ct/show/NCT00427674?order=1[LIST][*]Complete list of PD trials

Attachment 1410

Parkinson Pipeline Project
www.pdpipeline.org
Following theapies from pre-clinical development to approval in the Parkinson Pipeline Project Database (see homepage for link to database)

Attachment 1410